Javascript must be enabled to continue!
Ankylosing spondylitis and non-radiographic axial spondyloarthritis: Two stages of disease?
View through CrossRef
Aim. To compare the clinical manifestations of ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nrAxSpA). Subjects and methods. A Moscow early spondyloarthritis cohort has now included 132 patients with axial spondyloarthritis, of whom 69 patients who have been followed up at least 12 months are to be involved in a preliminary analysis. The mean age at the time of inclusion in the study was 28.1±5.5 years; the mean disease duration was 24.7±15.8 months; 63 (91.3%) patients were HLA-B27 positive; 41 and 28 included patients were diagnosed with AS and nrAxSpA, respectively. Results. Men were significantly more in the AS group than in the nrAxSpA group (58.5 and 32.1%, respectively; p=0.05). The patients of the two groups did not differ in main clinical parameters (the presence of arthritis and enthesitis), disease activity (BASDAI, ASDAS-CRP) and functional status (BASFI). All indicators of inflammatory activity decreased nearly 2-fold in both groups after 12 months of follow up. In 7 (25%) patients with nrAxSpA, radiologically detectable sacroiliitis (SI) developed over 12 months and the diagnosis of AS was verified. Among them, 2 (28.5%) patients had initially active SI detected by magnetic resonance imaging (MRI); 4 (57.1%) had chronic SI, and 1 (14.4%) had no pathological MRI changes. Conclusion. Due to the fact that the clinical manifestations of AS and nrAxSpA are comparable, it can be assumed that the latter is an early stage of AS.
Title: Ankylosing spondylitis and non-radiographic axial spondyloarthritis: Two stages of disease?
Description:
Aim.
To compare the clinical manifestations of ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nrAxSpA).
Subjects and methods.
A Moscow early spondyloarthritis cohort has now included 132 patients with axial spondyloarthritis, of whom 69 patients who have been followed up at least 12 months are to be involved in a preliminary analysis.
The mean age at the time of inclusion in the study was 28.
1±5.
5 years; the mean disease duration was 24.
7±15.
8 months; 63 (91.
3%) patients were HLA-B27 positive; 41 and 28 included patients were diagnosed with AS and nrAxSpA, respectively.
Results.
Men were significantly more in the AS group than in the nrAxSpA group (58.
5 and 32.
1%, respectively; p=0.
05).
The patients of the two groups did not differ in main clinical parameters (the presence of arthritis and enthesitis), disease activity (BASDAI, ASDAS-CRP) and functional status (BASFI).
All indicators of inflammatory activity decreased nearly 2-fold in both groups after 12 months of follow up.
In 7 (25%) patients with nrAxSpA, radiologically detectable sacroiliitis (SI) developed over 12 months and the diagnosis of AS was verified.
Among them, 2 (28.
5%) patients had initially active SI detected by magnetic resonance imaging (MRI); 4 (57.
1%) had chronic SI, and 1 (14.
4%) had no pathological MRI changes.
Conclusion.
Due to the fact that the clinical manifestations of AS and nrAxSpA are comparable, it can be assumed that the latter is an early stage of AS.
Related Results
Cross-cultural adaptation and validation of Lithuanian questionnaires for the spondyloarthropathies
Cross-cultural adaptation and validation of Lithuanian questionnaires for the spondyloarthropathies
Original English questionnaires – Bath Ankylosing Spondylitis Functional Index, Bath Ankylosing Spondylitis Patient Global Score, and Bath Ankylosing Spondylitis Disease Activity I...
Serum Fetuin-A Level in Patients With Ankylosing Spondylitis and its Relationship With Clinical Parameters
Serum Fetuin-A Level in Patients With Ankylosing Spondylitis and its Relationship With Clinical Parameters
Objectives: This study aims to investigate the association of serum fetuin-A levels with disease activation and clinical parameters in ankylosing spondylitis (AS) patients.
Patien...
Efficacy and Safety of Iguratimod Combined with Yunke Injection in the Treatment of Ankylosing Spondylitis
Efficacy and Safety of Iguratimod Combined with Yunke Injection in the Treatment of Ankylosing Spondylitis
Background
Biologics and Janus kinase (JAK) inhibitors carry specific risks for Ankylosing Spondylitis patients at risk of tuberculosis infection or those with co...
Gut microbiota in axial spondyloarthritis : genetics, medications and future treatments
Gut microbiota in axial spondyloarthritis : genetics, medications and future treatments
Axial spondyloarthritis, also referred to as ankylosing spondylitis, is a chronic inflammatory condition that predominantly affects the axial spine but may also present with perip...
AYURVEDIC MANAGEMENT OF ANKYLOSING SPONDYLITIS – A CASE REPORT
AYURVEDIC MANAGEMENT OF ANKYLOSING SPONDYLITIS – A CASE REPORT
Ankylosing spondylitis (AS) is a chronic, systemic, inflammatory disease that affects primarily sacroiliac joints and the spine. It is a gradually progressive condition over severa...
PROGNOSTIC VALUE OF FECAL MARKERS IN THE DIAGNOSIS OF AXIAL SPONDYLOARTHRITIS ASSOCIATED WITH CROHN’S DISEASE
PROGNOSTIC VALUE OF FECAL MARKERS IN THE DIAGNOSIS OF AXIAL SPONDYLOARTHRITIS ASSOCIATED WITH CROHN’S DISEASE
Introduction. Spondyloarthritis is presented by various chronic diseases, including classical axial
spondyloarthritis and spondyloarthritis associated with inflammatory bowel disea...
Turkish Version of Evaluation of Ankylosing Spondylitis Quality of Life Questionnaire in Patients With Ankylosing Spondylitis: A Validation and Reliability Study
Turkish Version of Evaluation of Ankylosing Spondylitis Quality of Life Questionnaire in Patients With Ankylosing Spondylitis: A Validation and Reliability Study
Objectives: This study aims to translate the Evaluation of Ankylosing Spondylitis Quality of Life (EASi-QoL) into the Turkish language and test its validity and reliability.
Patie...
Real-life data on the comorbidities in spondyloarthritis from our multicenter nationwide registry: BioStar
Real-life data on the comorbidities in spondyloarthritis from our multicenter nationwide registry: BioStar
Objectives: Considering that the comorbid situations during the management of Spondyloarthritis (SpA) have been underlined in several recommendations, the main objective of this st...

